

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

PrKALYDECO®

Ivacaftor tablets 150 mg, Oral

Ivacaftor granules 25 mg per packet, 50 mg per packet, 75 mg per packet, Oral

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator

ATC R07AX02

Distributed by:
Vertex Pharmaceuticals (Canada) Incorporated
20 Bay Street, Suite 1520
Toronto, Ontario
M5J 2N8

Date of Initial Approval:
Nov 26, 2012

Date of Revision:
Aug 24, 2021

Submission Control Number: 247481

RECENT MAJOR LABEL CHANGES

1 Indications, 1.1 Pediatrics	08/2021
4 Dosage and Administration	08/2021
7 Warnings and Precautions	08/2021

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

RECENT MAJOR LABEL CHANGES	2
TABLE OF CONTENTS	2
PART I: HEALTH PROFESSIONAL INFORMATION	4
1 INDICATIONS	4
1.1 Pediatrics.....	4
1.2 Geriatrics.....	4
2 CONTRAINDICATIONS	4
4 DOSAGE AND ADMINISTRATION	4
4.1 Dosing Considerations.....	4
4.2 Recommended Dose and Dosage Adjustment.....	5
4.4 Administration	7
4.5 Missed Dose.....	8
5 OVERDOSAGE	8
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	9
7 WARNINGS AND PRECAUTIONS	10
7.1 Special Populations.....	11
7.1.1 Pregnant Women.....	11
7.1.2 Breast-feeding	11
7.1.3 Pediatrics	12
7.1.4 Geriatrics	12
8 ADVERSE REACTIONS	12
8.1 Adverse Reaction Overview	12
8.2 Clinical Trial Adverse Reactions	13
8.2.1 Clinical Trial Adverse Reactions (Pediatrics).....	14
8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data	14
9 DRUG INTERACTIONS	15
9.2 Drug Interactions Overview.....	15

9.4	Drug-Drug Interactions	15
9.5	Drug-Food Interactions	18
9.6	Drug-Herb Interactions	18
10	CLINICAL PHARMACOLOGY	18
10.1	Mechanism of Action	18
10.2	Pharmacodynamics.....	19
10.3	Pharmacokinetics	20
11	STORAGE, STABILITY AND DISPOSAL.....	23
12	SPECIAL HANDLING INSTRUCTIONS.....	23
	PART II: SCIENTIFIC INFORMATION	24
13	PHARMACEUTICAL INFORMATION	24
14	CLINICAL TRIALS	24
14.1	Trial Design and Study Demographics	24
15	MICROBIOLOGY	32
16	NON-CLINICAL TOXICOLOGY	32
	PATIENT MEDICATION INFORMATION.....	35

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

KALYDECO (ivacaftor) tablets (150 mg) are indicated for the treatment of patients with cystic fibrosis (CF) aged 6 years and older and weighing 25 kg or more who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: *G551D*, *G1244E*, *G1349D*, *G178R*, *G551S*, *S1251N*, *S1255P*, *S549N* or *S549R*. KALYDECO tablets (150 mg) are also indicated for the treatment of cystic fibrosis (CF) in patients age 18 years and older with an *R117H* mutation in the *CFTR* gene.

KALYDECO (ivacaftor) granules (25 mg, 50 mg and 75 mg) are indicated for the treatment of children with cystic fibrosis (CF) aged 4 months and older and weighing 5 kg to less than 25 kg who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene: *G551D*, *G1244E*, *G1349D*, *G178R*, *G551S*, *S1251N*, *S1255P*, *S549N* or *S549R*.

Limitation of use: KALYDECO is not effective in patients with CF who are homozygous for the *F508del* mutation in the *CFTR* gene.

1.1 Pediatrics

Pediatrics (<4 months of age): No data in patients less than 4 months of age and weighing less than 5 kg, are available to Health Canada; therefore, Health Canada has not authorized the use of KALYDECO in this age group.

1.2 Geriatrics

Geriatrics (≥ 65 years of age): The efficacy and safety of KALYDECO in patients age 65 years or older have not been established.

2 CONTRAINDICATIONS

KALYDECO is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

KALYDECO should only be administered to patients who have a mutation in the *CFTR* gene listed in INDICATIONS. KALYDECO should only be prescribed by physicians with experience in the treatment of cystic fibrosis. If the patient's genotype is unknown, an accurate and validated genotyping method should be performed to confirm the presence of an indicated mutation in at least one allele of the *CFTR* gene [see 10 CLINICAL PHARMACOLOGY and 14 CLINICAL TRIALS].

KALYDECO dosing is impacted in the following groups:

- Hepatic Impairment – Moderate or severe hepatic impairment
- Renal Impairment – Severe renal impairment or end-stage renal disease

- Interactions with Medicinal Products
 - Concomitant use of moderate and strong CYP3A inhibitors
 - Concomitant use of strong CYP3A inducers
- Elevated transaminase (AST/ALT) levels - patients with ALT or AST >5 x upper limit of normal (ULN)

4.2 Recommended Dose and Dosage Adjustment

Adults, adolescents, and children aged 4 months and older

Adults, adolescents, and children aged 4 months and older should be dosed according to Table 1.

Age	Body Weight (kg)	KALYDECO Dose*		Total Daily Dose
		Morning	Evening	
4 to <6 months	5 kg or more	1 packet (25 mg)	1 packet (25 mg)	50 mg/day
	≥5 kg to <7 kg	1 packet (25 mg)	1 packet (25 mg)	50 mg/day
6 months and older	≥7 kg to <14 kg	1 packet (50 mg)	1 packet (50 mg)	100 mg/day
	≥14 kg to <25 kg	1 packet (75 mg)	1 packet (75 mg)	150 mg/day
	≥25 kg	1 tablet (150 mg)	1 tablet (150 mg)	300 mg/day

* dose should be taken orally approximately 12 hours apart with fat-containing food.

Health Canada has not authorized an indication for use in pediatric patients less than 4 months of age [see 7.1 Special Populations and 10.3 Pharmacokinetics].

Hepatic Impairment

Patients aged 4 months to less than 6 months

Due to variability in maturation of cytochrome (CYP) enzymes involved in ivacaftor metabolism, treatment with KALYDECO is not recommended in patients aged 4 months to less than 6 months with hepatic impairment.

Patients aged 6 months and older

No dose adjustment is necessary for patients aged 6 months and older with mild hepatic impairment (Child-Pugh Class A).

The dose of KALYDECO should be one tablet or one packet of granules once daily for patients aged 6 months and older with moderate hepatic impairment (Child-Pugh Class B).

There is no experience in the use of KALYDECO in patients aged 6 months and older with severe hepatic impairment (Child-Pugh Class C) and therefore its use is not recommended unless the benefits outweigh the risks. In such cases, KALYDECO should be administered at a starting dose of one tablet or one packet of granules every other day and modified according to tolerability and clinical response. For dose adjustment for patients with hepatic impairment, refer to Table 2.

Table 2: Dosing Recommendations by Body Weight in Patients Aged 6 Months and Older for Patients with Hepatic Impairment†

Hepatic Impairment	Weight	Dosing
Mild (Child-Pugh Class A)	≥5 kg to <7 kg	No Dosage adjustment
	≥7 kg to <14 kg	
	≥14 kg to <25 kg	
	≥25 kg	
Moderate (Child-Pugh Class B)	≥5 kg to <7 kg	1 packet (25 mg) once daily
	≥7 kg to <14 kg	1 packet (50 mg) once daily
	≥14 kg to <25 kg	1 packet (75 mg) once daily
	≥25 kg	1 tablet (150 mg) once daily
Severe (Child-Pugh Class C)	≥5 kg to <7 kg	Not recommended unless the benefit outweighs the risk. <u>Dose as follows in such cases:</u> 1 packet (25 mg) every other day*
	≥7 kg to <14 kg	Not recommended unless the benefit outweighs the risk. <u>Dose as follows in such cases:</u> 1 packet (50 mg) every other day*
	≥14 kg to <25 kg	Not recommended unless the benefit outweighs the risk. <u>Dose as follows in such cases:</u> 1 packet (75 mg) every other day*
	≥25 kg	Not recommended unless the benefit outweighs the risk. <u>Dose as follows in such cases:</u> 1 tablet (150 mg) every other day*
*Dosing intervals should be modified according to clinical response and tolerability.		
† Not recommended in patients aged 4 to 6 months		

Renal Impairment

No dosage adjustment is necessary for mild to moderate renal impairment. Caution is recommended while using KALYDECO in patients with severe renal impairment (creatinine clearance less than or equal to 30 mL/min) or end stage renal disease [see 7 WARNINGS AND PRECAUTIONS and 10.3 Pharmacokinetics].

Concomitant use of CYP3A inhibitors

Patients aged 4 months to less than 6 months

Due to variability in maturation of cytochrome (CYP) enzymes involved in ivacaftor metabolism, treatment with ivacaftor is not recommended when co-administered with moderate or strong inhibitors of CYP3A in patients aged 4 months to less than 6 months [see 7 WARNINGS AND PRECAUTIONS and 9.4 Drug-Drug Interactions].

Patients aged 6 months and older

The dose of KALYDECO should be adjusted when co-administered with moderate and strong CYP3A inhibitors [see 7 WARNINGS AND PRECAUTIONS and 9.4 Drug-Drug Interactions].

See Table 3 for recommended dosing adjustments when co-administered with strong CYP3A inhibitors (e.g., ketoconazole).

Body Weight (kg)	KALYDECO Dose*
≥5 kg to <7 kg	1 packet (25 mg) twice a week, approximately 3 to 4 days apart.
≥7 kg to <14 kg	1 packet (50 mg) twice a week, approximately 3 to 4 days apart.
≥14 kg to <25 kg	1 packet (75 mg) twice a week, approximately 3 to 4 days apart.
≥25 kg	1 tablet (150 mg) twice a week, approximately 3 to 4 days apart.

*Dosing intervals should be modified according to clinical response and tolerability
† Not recommended in patients aged 4 to 6 months

See Table 4 for recommended dosing adjustments when co-administered with moderate CYP3A inhibitors (e.g., fluconazole).

Body Weight (kg)	KALYDECO Dose*
≥5 kg to <7 kg	1 packet (25 mg) once daily
≥7 kg to <14 kg	1 packet (50 mg) once daily
≥14 kg to <25 kg	1 packet (75 mg) once daily
≥25 kg	1 tablet (150 mg) once daily

*Dosing intervals should be modified according to clinical response and tolerability
† Not recommended in patients aged 4 to 6 months

Concomitant use of strong CYP3A inducers

Co administration with strong CYP3A inducers (e.g. rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin, and St. John's wort (*Hypericum perforatum*)) is not recommended [see 7 WARNINGS AND PRECAUTIONS and 9.4 Drug-Drug Interactions].

Elevated transaminase (AST/ALT) levels

Elevated transaminases have been reported in patients with CF treated with KALYDECO. Dosing should be interrupted in patients with ALT or AST of > 5 x upper limit of normal (ULN). Following resolution of transaminase elevations, consider the benefits and risks of resuming KALYDECO [see 4.2 Recommended Dose and Dosage Adjustment and 8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data].

4.4 Administration

KALYDECO tablets and granules should be taken with fat-containing food. Meals and snacks

recommended in CF guidelines or meals recommended in standard nutritional guidelines contain adequate amounts of fat. A serving size of foods appropriate for age from a typical CF diet should be given. Examples of meals that contain fat are those prepared with butter or oils or those containing eggs, cheeses, nuts, whole milk, breast milk, infant formula, or meats. Food containing grapefruit should be avoided. [see 9.5 Drug-Food Interactions and 10.3 Pharmacokinetics].

Granules

- For oral use.
- The entire contents of each packet of granules should be mixed with 1 teaspoon (5 mL) of age-appropriate soft food or liquid and completely consumed.
- Food or liquid should be at or below room temperature.
- Each packet is for single use only. Once mixed, the product has been shown to be stable for 1 hour, and therefore should be consumed during this period.
- Some examples of soft foods or liquids may include puréed fruits or vegetables, yogurt, applesauce, water, breast milk, infant formula, milk, or juice (except for grapefruit juice).
- Each dose should be administered just before or just after fat-containing food. If mixed with food, KALYDECO granules must not be stored for future use.

Tablets

For oral use. Patients should be instructed to swallow the tablets whole (e.g., patients should not chew, break, or dissolve the tablet).

4.5 Missed Dose

If a dose is missed within 6 hours of the scheduled time, the missed dose should be taken as soon as possible with fat-containing food.

If more than 6 hours have passed since the dose should have been taken, this dose should be skipped, and the usual dosing schedule resumed.

5 OVERDOSAGE

There have been no reports of overdose with KALYDECO.

Ivacaftor doses as high as 500 mg/kg in rats and 2000 mg/kg in mice were administered. These doses are 13- and 27-fold higher, respectively, than the intended daily therapeutic dose of 300 mg for ivacaftor for patients 6 years and older.

The highest single dose used in a clinical trial was 800 mg in a solution formulation without any treatment-related adverse events.

The highest repeated dose was 450 mg (in a tablet formulation) every 12 hours for 4.5 days (9 doses) in a trial evaluating the effect of KALYDECO on electrocardiograms (ECGs) in healthy subjects. Adverse events reported at a higher incidence compared to placebo included dizziness and diarrhea.

No specific antidote is available for overdose with KALYDECO. Treatment of overdose with KALYDECO consists of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 5 – Dosage Forms, Strengths, Composition and Packaging.

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Oral	Granules 25 mg, 50 mg and 75 mg	Colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, mannitol, sucralose, and sodium lauryl sulfate
Oral	Tablets 150 mg	<p><i>Tablet Core</i> Colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate</p> <p><i>Tablet Film-Coat</i> Carnauba wax, indigo carmine aluminum lake, PEG 3350, polyvinyl alcohol, talc, and titanium dioxide</p> <p><i>Printing Ink:</i> Ammonium hydroxide, iron oxide black, propylene glycol, and shellac.</p>

KALYDECO 25 mg, 50 mg, or 75 mg granules

White to off-white granules (sweetened but unflavored) and enclosed in a unit dose packet containing 25 mg of ivacaftor, 50 mg of ivacaftor or 75 mg of ivacaftor.

KALYDECO 150 mg tablets

Light blue, capsule-shaped film-coated tablets printed with “V 150” in black ink on one side and plain on the other. Each tablet contains 150 mg of ivacaftor.

Nature and contents of container

KALYDECO tablets are packaged in a thermoform (polychlorotrifluoroethylene (PCTFE)/foil) blister or a high-density polyethylene (HDPE) bottle with a polypropylene, foil-lined induction seal closure and molecular sieve desiccant.

Pack Sizes

KALYDECO Tablets (150 mg):	Blister pack containing 56 film coated tablets. Bottle containing 60 film coated tablets.
KALYDECO Granules (25 mg):	56-count carton (contains 56-unit dose packets of 25 mg ivacaftor per packet)
KALYDECO Granules (50 mg):	56-count carton (contains 56-unit dose packets of 50 mg ivacaftor per packet)
KALYDECO Granules (75 mg):	56-count carton (contains 56-unit dose packets of 75 mg ivacaftor per packet)

7 WARNINGS AND PRECAUTIONS

Driving and Operating Machinery

Dizziness has been reported in patients receiving KALYDECO, which could influence the ability to drive or operate machines [see 8.2 Clinical Trial Adverse Reactions]. Patients experiencing dizziness should be advised not to drive or operate machines until symptoms abate.

In the case of children, KALYDECO should be taken under parental or caregiver supervision. Children should be cautioned against riding bicycles or doing other activities that require them to be alert until it is known how KALYDECO will affect them.

Hepatic/Biliary/Pancreatic

Effect on Liver Function Tests

Elevated transaminases (alanine transaminase [ALT] or aspartate transaminase [AST]) have been reported in patients with CF receiving KALYDECO [see 4.2 Recommended Dose and Dosage Adjustment and 8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data].

Hepatic Impairment

Use of KALYDECO is not recommended in patients with severe hepatic impairment unless the benefits are expected to outweigh the risks of overexposure. In such cases of severe hepatic impairment or for patients with moderate hepatic impairment aged 6 months and older a reduced dose of KALYDECO is recommended [see 4.2 Recommended Dose and Dosage Adjustment and 10.3 Pharmacokinetics].

Use of KALYDECO is not recommended in patients aged 4 months to less than 6 months with mild, moderate or severe hepatic impairment [see 4.2 Recommended Dose and Dosage Adjustment, Hepatic Impairment].

Concomitant Use with CYP3A Inhibitors or Inducers

Ivacaftor is a substrate of CYP3A. Medicinal products that inhibit or induce CYP3A activity may impact the pharmacokinetics of ivacaftor.

For patients 6 months and older the dose of KALYDECO must be adjusted when concomitantly used with strong or moderate CYP3A inhibitors [see 4.2 Recommended Dose and Dosage Adjustment and 9.4 Drug-Drug Interactions].

Use of KALYDECO is not recommended in patients aged 4 months to less than 6 months when co-administered with moderate or strong CYP3A inhibitors [see 4.2 Recommended Dose and Dosage Adjustment, Concomitant use of CYP3A inhibitors].

Exposure to ivacaftor may be reduced by the concomitant use of CYP3A inducers, potentially resulting in loss of KALYDECO efficacy [see 4.2 Recommended Dose and Dosage Adjustment and 9.4 Drug-Drug Interactions].

Monitoring and Laboratory Tests

Effect on Liver Function Tests

Elevated transaminases have been reported in patients with CF treated with KALYDECO. It is recommended that ALT and AST be assessed prior to initiating KALYDECO, every 3 months during the first year of treatment, and annually thereafter. For patients with a history of transaminase elevations, more frequent monitoring of liver function tests should be considered. Patients who develop increased transaminase levels should be closely monitored until the

abnormalities resolve. Dosing should be interrupted in patients with ALT or AST of greater than 5 x upper limit of normal (ULN). Following resolution of transaminase elevations, consider the benefits and risks of resuming KALYDECO dosing [see 4.2 Recommended Dose and Dosage Adjustment and 8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data].

Patients should be advised to contact their doctor immediately if they develop symptoms suggestive of increased transaminases (e.g., abdominal pain, anorexia, jaundice, dark urine, pale stools, pruritus).

Ophthalmologic

Cataracts

Cases of non-congenital lens opacities, without impact on vision, have been reported in pediatric patients treated with KALYDECO. Although other risk factors were present in some cases, such as corticosteroid use and exposure to radiation, a possible risk attributable to KALYDECO cannot be excluded. Baseline and follow up ophthalmological examinations are recommended in pediatric patients initiating KALYDECO treatment [see 16 NON-CLINICAL TOXICOLOGY].

Renal

Caution is recommended while using KALYDECO in patients with severe renal impairment (creatinine clearance less than or equal to 30 mL/min) or end stage renal disease [see 4.2 Recommended Dose and Dosage Adjustment and 10.3 Pharmacokinetics].

Reproductive Health: Female and Male Potential

Fertility

There are no data available on the effect of KALYDECO on fertility in humans. KALYDECO had an effect on fertility in rats [see 16 NON-CLINICAL TOXICOLOGY].

7.1 Special Populations

7.1.1 Pregnant Women

No adequate and well-controlled studies of KALYDECO have been conducted in pregnant women. Because animal reproduction studies are not always predictive of human response, KALYDECO should be used during pregnancy only if the expected benefit to the patient clearly outweighs the potential risk to the fetus.

Ivacaftor was not teratogenic in rats at approximately 5 times the maximum recommended human dose (MRHD) (based on summed AUCs for ivacaftor and its major metabolites at a maternal dose of 200 mg/kg/day). Ivacaftor was not teratogenic in rabbits at approximately 11 times the MRHD (based on the AUC for ivacaftor at a maternal dose of 100 mg/kg/day). Ivacaftor decreased the fertility index in female rats and the number of corpora lutea, implantations and viable embryos at 200 mg/kg/day when dams were dosed prior to and during early pregnancy [see 16 NON-CLINICAL TOXICOLOGY]. Placental transfer of ivacaftor was observed in pregnant rats and rabbits.

7.1.2 Breast-feeding

Ivacaftor is excreted into the milk of lactating female rats. Excretion of ivacaftor into human milk is probable. There are no human trials that have investigated the effects of ivacaftor on breastfed infants. The use of KALYDECO by nursing women should only be considered if the expected benefit to the patient outweighs the potential risk to the breastfed infant.

7.1.3 Pediatrics

Pediatrics (<4 months of age): No data in patients less than 4 months of age, weighing less than 5 kg, are available to Health Canada; therefore, Health Canada has not authorized the use of KALYDECO in this age group.

With regard to the *R117H* mutation in the *CFTR* gene, the efficacy of KALYDECO in patients 6 to 17 years of age has not been adequately established at this time, and the safety data are included in the safety profile of Trial 5 [see 8.2 Clinical Trial Adverse Reactions].

7.1.4 Geriatrics

The efficacy and safety of KALYDECO in patients age 65 years or older have not been established.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

The overall safety profile of KALYDECO is based on pooled data from Trials 1, 2, and 3, which included 353 patients 6 years of age and older with CF. Of these 353 patients, 221 received KALYDECO and 132 received placebo for 16 to 48 weeks. The proportion of patients who prematurely discontinued study drug due to adverse events was 2% for KALYDECO-treated patients and 5% for placebo-treated patients. The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%). The most common serious adverse reactions, occurring in more than one KALYDECO-treated patient, were abdominal pain, increased hepatic enzymes, and hypoglycemia, all of which occurred in less than 1% of patients.

The safety profile of KALYDECO is based on seven clinical trials:

- Trials 1 and 2: Two 48-week, placebo-controlled clinical trials in 213 patients with CF ages 6 to 53 (109 received ivacaftor and 104 received placebo) who had a *G551D* mutation in the *CFTR* gene and who were treated with KALYDECO 150 mg orally or placebo twice daily.
- Trial 3: A 16-week, placebo-controlled trial in 140 patients with CF ages 12 to 52 who were homozygous for the F508del mutation.
- Trial 4: An 8-week crossover design study involving 39 patients with CF between the ages of 6 and 57 years with a *G1244E*, *G1349D*, *G178R*, *G551S*, *G970R*, *S1251N*, *S1255P*, *S549N*, or *S549R* mutation in the *CFTR* gene.
- Trial 5: A 24-week, placebo-controlled trial involving 69 patients with CF between the ages of 6 and 68 years with an *R117H* mutation in the *CFTR* gene.
- Trial 6: A 24-week, open-label trial in 34 patients with CF, 2 to less than 6 years of age with a *G551D*, *G1244E*, *G1349D*, *G178R*, *G551S*, *G970R*, *S1251N*, *S1255P*, *S549N*, or *S549R* mutation in the *CFTR* gene. Of 34 patients enrolled, 32 had the *G551D* mutation and 2 had the *S549N* mutation.
- Trial 7: A 24-week, open-label trial involving a cohort of 19 patients with CF aged 12 months to less than 24 months, a cohort of 11 patients aged 6 months to less than 12 months, and a cohort of 6 patients aged 4 months to less

than 6 months. Patients with a *G551D*, *G1244E*, *G1349D*, *G178R*, *G551S*, *S1251N*, *S1255P*, *S549N*, or *S549R* mutation were eligible for this study.

8.2 Clinical Trial Adverse Reactions

Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

Patients with CF Over 6 Years of Age with a G551D Gating Mutation (Trials 1 and 2)

The incidence of adverse reactions below is based upon the pooled analyses of Trials 1 and 2. Table 6 shows adverse reactions occurring in at least 5% of KALYDECO-treated patients that also occurred with an incidence of at least 3% more than placebo.

Table 6: Incidence of Adverse Drug Reactions in at Least 5% of KALYDECO-Treated Patients 6 years and older with the G551D Mutation in the CFTR Gene in two Phase 3 Trials (Trials 1 and 2) with an Incidence of at Least 3% More than Placebo			
System Organ Class (SOC)	Adverse Reactions (Preferred Term)	KALYDECO N = 109 (%)	Placebo N = 104 (%)
Infections and infestations	Upper respiratory tract infection (URTI)	24 (22)	14 (14)
	Nasopharyngitis	16 (15)	12 (12)
	Rhinitis	8 (7)	4 (4)
Nervous system disorders	Headache	26 (24)	17 (16)
	Dizziness	10 (9)	1 (1)
Respiratory, thoracic and mediastinal disorders	Nasal congestion	22 (20)	16 (15)
	Oropharyngeal pain	24 (22)	19 (18)
	Sinus congestion	8 (7)	4 (4)
	Pharyngeal erythema	22 (20)	0 (0)
Gastrointestinal	Abdominal pain	17 (16)	13 (13)
	Diarrhea	14 (13)	10 (10)
Skin and subcutaneous tissue disorders	Rash	14 (13)	7 (7)
Investigations	Bacteria in sputum	8 (7)	4 (4)

The safety profile for the CF patients enrolled in the other clinical trials (Trials 3, 7) was similar to that observed in the 48-week, placebo-controlled trials (Trials 1 and 2).

Upper Respiratory Tract Events

During Trials 1 and 2, the incidence of several upper respiratory tract events was higher in KALYDECO-treated patients than placebo. URTI was reported in 22% of KALYDECO-treated patients compared to 14% in the placebo group. Other respiratory tract events occurring in KALYDECO-treated patients with an incidence of at least 3% more than placebo included oropharyngeal pain (22%), nasal congestion (20%), nasopharyngitis (15%), rhinitis (7%), and sinus congestion (7%). None of those events were serious and no patients in the KALYDECO-treated group discontinued treatment because of upper respiratory tract events.

8.2.1 Clinical Trial Adverse Reactions (Pediatrics)

The safety profile is generally consistent among pediatric and adult patients. Pediatric patients under the age of 4 months old, weighing less than 5 kg have not been studied.

8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

Laboratory Abnormalities

Transaminase Elevations

The incidence of maximum transaminase (ALT or AST) in patients 6 years and older (Trials 1, 2, and 3) are presented in Table 7. Two patients (2%) on placebo and 1 patient (0.5%) on KALYDECO permanently discontinued treatment for elevated transaminases, all >8 x ULN. Two patients treated with KALYDECO were reported to have serious adverse reactions of elevated liver transaminases compared to none on placebo.

Threshold Analysis Criteria ALT or AST	Kalydeco N = 221	Placebo N = 132
>3 × ULN	6%	8%
>5 × ULN	2%	2%
>8 × ULN	2%	2%

ALT: alanine aminotransferase; AST: aspartate aminotransferase

The incidence of patients experiencing transaminase elevations (ALT or AST) in patients 4 months to less than 6 years of age (Trials 6 and 7) are presented in Table 8.

In Trial 6, transaminase elevations were more common in patients who had abnormal transaminases at baseline. KALYDECO was permanently discontinued in 1 patient in this study.

In Trial 7, there were two patients (11%) with elevations of ALT or AST >8 x ULN and both had treatment with ivacaftor interrupted. No patients had elevations in total bilirubin or discontinued ivacaftor treatment due to transaminase elevations in any cohort.

Threshold Analysis Criteria ALT or AST	2 years to <6 years N = 34	12 months to <24 months N = 18	6 months to <12 months N = 11	4 months to <6 months N = 6
>3 × ULN	15%	28%	9%	0%
>5 × ULN	15%	11%	0%	0%
>8 × ULN	15%	11%	0%	0%

ALT: alanine aminotransferase; AST: aspartate aminotransferase
--

Patients should be advised to contact their doctor immediately if they develop symptoms suggestive of increased transaminases (e.g., abdominal pain, anorexia, jaundice, dark urine, pale stools, pruritus).

9 DRUG INTERACTIONS

9.2 Drug Interactions Overview

Ivacaftor is a sensitive CYP3A substrate. Any medicinal products that modify CYP3A activity may impact the pharmacokinetics of ivacaftor. Ivacaftor is also a weak inhibitor of CYP3A and P-gp. Administration of KALYDECO may increase systemic exposure to medicinal products that are substrates of CYP3A or P-gp, which could increase or prolong their therapeutic effect and adverse reactions. Concomitant use of KALYDECO may increase the concentrations of medicinal products that are substrates of CYP2C9. Caution is warranted when co-administration is required.

9.4 Drug-Drug Interactions

The drugs listed in Table 9 are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

Table 9 - Established or Potential Drug-Drug Interactions Between Ivacaftor and CYP3A Inhibitor			
Drug	Source of Evidence	Effect	Clinical comment
Strong CYP3A Inhibitors			
Rifampin	CT	↓ AUC _{0-∞} 9-fold in IVA	Co-administration is not recommended.
Phenobarbital	T	↓ IVA exposure potential	
Carbamazepine			
Phenytoin			
Strong CYP3A Inhibitors			
Ketoconazole	CT	↑ 8.5 × AUC _{0-∞} , Substantially increased exposure	Reduction of ivacaftor dose to 1 tablet or 1 packet twice a week.*
Itraconazole Posaconazole Voriconazole Clarithromycin	T	↑ IVA exposure potential	Reduction of ivacaftor dose to 1 tablet or 1 packet twice a week.*
Moderate CYP3A Inhibitors			
Fluconazole	CT	↑ 3 × AUC _{0-12h} , Increased exposure	Reduction of ivacaftor dose to 1 tablet or 1 packet once daily.*
Erythromycin	T	↑ IVA exposure potential	Reduction of ivacaftor dose to 1 tablet or 1 packet once daily.*
* Co-administration of ivacaftor with strong or moderate CYP3A inhibitors is <i>not recommended for patients 4 to less than 6 months of age</i> . See 4.2 Recommended Dose and Dosage Adjustment.			
↑ = increase, ↓ = decrease			
Legend: C = Case Study; CT = Clinical Trial; T = Theoretical; AUC = Area Under the Curve			

Effect of Other Drugs on KALYDECO

CYP3A Inducers

Co-administration of KALYDECO with rifampin, a strong CYP3A inducer, decreased ivacaftor exposure (AUC) by approximately 9-fold. Therefore, co-administration with strong CYP3A inducers, such as rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin, and St John's wort (*Hypericum perforatum*), is not recommended. Concomitant use of a moderate CYP3A inducer may decrease the exposure of ivacaftor and thus may reduce KALYDECO efficacy. No dose adjustment is recommended when KALYDECO is used with weak CYP3A inducers [see

4.2 Recommended Dose and Dosage Adjustment and 7 WARNINGS AND PRECAUTIONS].

CYP3A Inhibitors

Co-administration of KALYDECO with ketoconazole, a strong CYP3A inhibitor, increased ivacaftor exposure (AUC) by 8.5-fold in healthy adults. Therefore, the dose of KALYDECO should be reduced when co-administered with strong CYP3A inhibitors for patients 6 months and older. Co-administration of ivacaftor with fluconazole, a moderate inhibitor of CYP3A, increased ivacaftor exposure by 3-fold in healthy adults. The dose of KALYDECO should be reduced when co-administered with moderate CYP3A inhibitors for patients 6 months and older [see Table 3 and 4 in 4.2 Recommended Dose and Dosage Adjustment and 7 WARNINGS AND PRECAUTIONS]. Co-administration of KALYDECO with moderate or strong CYP3A inhibitors is not recommended for patients 4 to less than 6 months of age.

Ciprofloxacin

Co-administration with ciprofloxacin had no effect on the exposure of ivacaftor. No dose adjustment is necessary during concomitant administration of KALYDECO with ciprofloxacin.

The effects of ivacaftor on the exposures of co-administered drugs are shown in Table 10.

Table 10: Established or Potential Drug-Drug Interactions - Effect of Ivacaftor on Other Drugs			
Drug	Source of Evidence	Effect	Clinical comment
CYP3A substrates			
Midazolam	CT	↑ 1.5-fold midazolam AUC _{0-∞}	No dose adjustment for midazolam is recommended
CYP2C9 Substrates			
Warfarin	T	↑ IVA exposure potential	Monitoring the international normalized ratio (INR) during co-administration with warfarin is recommended
P-Glycoprotein Substrates			
Digoxin	CT	↑ 1.3-fold Digoxin	Caution is warranted and therapeutic concentration monitoring of sensitive p-gp substrate is recommended
Cyclosporine	T	↑ IVA exposure potential	
Everolimus			
Sirolimus Tacrolimus			
CYP2D6 Substrates			
Desipramine	CT	↔	No dose adjustment for desipramine or CYP2D6 substrates is recommended
CYP2C8 Substrates			
Rosiglitazone	CT	↔	No dose adjustment for rosiglitazone or CYP2C8 substrates is recommended
Hormonal Contraceptives			
Oral Contraceptive	CT	↔	No dose adjustment of the hormonal contraceptives is recommended

↑ = increase, ↔ = no change
Legend: CT = Clinical Trial; T = Theoretical

Effect of KALYDECO on Other Drugs

CYP3A, P-gp, or CYP2C9 Substrates

Based on pre-clinical studies, ivacaftor and its M1 metabolite have the potential to inhibit CYP3A and P-gp. In humans, co-administration with oral midazolam, a sensitive CYP3A substrate, increased midazolam exposure 1.5-fold, consistent with weak inhibition of CYP3A by ivacaftor. Co-administration with digoxin, a sensitive P-gp substrate, increased digoxin exposure by 1.3-fold, consistent with the weak inhibition of P-gp. Administration of KALYDECO may increase systemic exposure of drugs that are substrates of CYP3A and/or P-gp, which may increase or prolong their therapeutic effect and adverse events. Use with caution and monitor for benzodiazepine related side effects when using oral midazolam, alprazolam, diazepam, or triazolam. Use with caution and appropriate monitoring when co-administering KALYDECO with sensitive CYP3A and/or P-gp substrates such as digoxin, cyclosporine, or tacrolimus.

Ivacaftor may inhibit CYP2C9. Therefore, monitoring the international normalized ratio (INR) during co-administration with warfarin is recommended.

CYP2C8 Substrates

KALYDECO has been studied with rosiglitazone a CYP2C8 substrate and was found to have no significant effect on the exposures of rosiglitazone. No dose adjustment of rosiglitazone or other CYP2C8 substrates is recommended.

CYP2D6 Substrates

KALYDECO has been studied with desipramine a CYP2D6 substrate and was found to have no significant effect on the exposures of desipramine. No dose adjustment of desipramine or other CYP2D6 substrates is recommended.

Hormonal contraceptives

Ivacaftor has been studied with an estrogen/progesterone oral contraceptive and was found to have no significant effect on the exposures of the oral contraceptive. Ivacaftor is not expected to modify the efficacy of oral contraceptives. Therefore, no dose adjustment of oral contraceptives is necessary.

9.5 Drug-Food Interactions

Grapefruit juice contains one or more components that moderately inhibit CYP3A, and its co-administration may increase plasma concentrations of ivacaftor. Food containing grapefruit should be avoided during treatment with KALYDECO [see 4.4 Administration].

9.6 Drug-Herb Interactions

Co-administration of KALYDECO with herbal products that strongly induce CYP3A (e.g., St. John's wort) may decrease efficacy and is not recommended.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Ivacaftor is a selective potentiator of the CFTR protein. The CFTR protein is a chloride channel

present at the surface of epithelial cells in multiple organs. Ivacaftor increases chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein.

The *G970R* mutation has been identified as causing a splicing defect resulting in little-to-no CFTR protein at the cell surface able to be potentiated by ivacaftor.

10.2 Pharmacodynamics

Ivacaftor potentiated chloride transport of *G551D*-CFTR protein *in vitro*, in both recombinant rodent cells carrying this mutation and in human bronchial epithelial (HBE) cells isolated from the bronchi of a patient with CF carrying both the *G551D* and *F508del* mutations. In the *G551D*-CFTR recombinant rodent cells, ivacaftor treatment resulted in a 55-fold increase over baseline chloride transport.

The pharmacological activity of the major circulating metabolites of ivacaftor in humans, M1 (hydroxymethyl-ivacaftor) and M6 (ivacaftor carboxylate), was tested in cultured *G551D/F508del*-HBE (Ussing chamber studies). The M1 metabolite potentiated CFTR-mediated chloride transport with approximately 1/6th the potency of ivacaftor and is considered pharmacologically active. The M6 metabolite showed <1/50th the potency of ivacaftor *in vitro* and is not considered to be pharmacologically active.

Safety Pharmacology

Ivacaftor was evaluated *in vitro* for off-target effects on a wide variety of receptors and enzymes in radioligand binding assays, as well as for interactions with a variety of ion channels. Ivacaftor did not potently bind to or alter the function of these targets, indicating a low potential for off-target effects. In electrophysiological studies, ivacaftor inhibited only CaV1.2 (IC₅₀=1.3 μM) and KV1.5 (IC₅₀=3.4 μM) with moderate potency and had little or no measurable activity (IC₅₀ >10 μM) on the other sodium, calcium, and potassium channels tested.

Ivacaftor produced concentration-dependent inhibition of hERG (human ether à-go-go related gene) tail currents, with an IC₁₅ of 5.5 μM. However, no ivacaftor-related QT prolongation was observed in a dog telemetry study at single doses up to 60 mg/kg or in ECG measurements from repeat-dose studies in dogs up to 1 year at 60 mg/kg/day. Ivacaftor produced a dose-related but transient increase in the blood pressure parameters in dogs at single oral doses up to 60 mg/kg.

Oral administration of ivacaftor did not cause adverse effects on the CNS or respiratory system in rats at single oral doses of up to 1000 mg/kg. Ivacaftor did not cause adverse effects on the cardiovascular system in telemetry studies at single oral doses up to 100 mg/kg in rats and 60 mg/kg in dogs. Ivacaftor produced an inhibition of gastric emptying and gastrointestinal transit in rats at single oral doses of 500 and 1000 mg/kg.

Sweat Chloride Evaluation

In clinical trials in patients with the *G551D* mutation in the *CFTR* gene, KALYDECO led to statistically significant reductions in sweat chloride concentration. In two randomized, double-blind, placebo-controlled clinical trials (Trial 1 in patients 12 and older and Trial 2 in patients 6 to 11 years of age), the treatment difference (between KALYDECO and placebo) in the mean change in sweat chloride from baseline through Week 24 was -48 mmol/L (95% CI - 51, -45) and -54 mmol/L (95% CI -62, -47), respectively. These changes persisted through 48-weeks.

In a clinical trial in patients with a *G1244E*, *G1349D*, *G178R*, *G551S*, *S1251N*, *S1255P*, *S549N*, *S549R*, or *G970R* mutation, KALYDECO led to a statistically significant reduction in

sweat chloride concentration. The treatment difference in the mean change from baseline in sweat chloride was -49 mmol/L (95% CI -57, -41) through 8 weeks of treatment. In this trial, mean changes in sweat chloride for the mutations for which KALYDECO is indicated ranged from -51 to -8, whereas the range for individual subjects with the *G970R* mutation was -1 to 11 mmol/L.

In an open-label, Phase 3 clinical trial in 34 patients ages 2 to <6 years with the above mutations, administered either 50 mg or 75 mg of ivacaftor twice daily (Trial 6), the mean absolute change from baseline in sweat chloride was -47 mmol/L (95% CI -58, -36) at Week 24.

In a randomized, double-blind, placebo-controlled clinical trial in patients with CF who have an *R117H* mutation in the *CFTR* gene (Trial 5), the mean baseline sweat chloride for patients 18 years and older was 71 mmol/L. The treatment difference in mean change in sweat chloride from baseline through 24 weeks of treatment for patients 18 years and older was -22 mmol/L (95% CI -26, -17).

In a 24 week, open-label, Phase 3 clinical trial (Trial 7) in patients with CF less than 24 months of age, the mean absolute change from baseline in sweat chloride for patients aged 12 months to less than 24 months (n=10) was -73.5 mmol/L (SD: 17.5) at week 24, the mean absolute change from baseline in sweat chloride for patients aged 6 months to less than 12 months (n=6) was -58.6 mmol/L (SD: 16.5) at week 24, and the mean absolute change from baseline in sweat chloride for patients aged 4 months to less than 6 months (n=3) was -50.0 mmol/L (SD: 17.3) at week 24.

Cardiac Electrophysiology

The effect of multiple doses of ivacaftor 150 mg and 450 mg twice daily on QTc interval was evaluated in a randomized, placebo- and active-controlled (moxifloxacin 400 mg), four-period crossover, thorough QT study in 72 healthy subjects. In a study with demonstrated ability to detect small effects, the upper bound of the one sided 95% confidence interval (CI) for the largest placebo-adjusted, baseline-corrected QTc based on Fridericia's correction method (QTcF) was below 10 ms, the threshold for regulatory concern.

10.3 Pharmacokinetics

The findings from *in vivo* absorption, distribution, metabolism, and elimination studies in the mouse, rat, rabbit, and dog showed that ivacaftor was rapidly absorbed following oral administration of aqueous suspensions with the extent of absorption ranging from 30% to 100%. Apparent permeability of ivacaftor *in vitro*, using a Caco-2-cell based assay, was high, which suggests that human intestinal absorption will be high following oral administration. Bi-directional transport studies conducted in Madin-Darby canine kidney (MDCK) cells with stably transfected human multi-drug resistance protein 1 (MDR1, also known as p-glycoprotein or P-gp) demonstrated that ivacaftor is not a P-gp efflux substrate. *In vitro* studies with recombinant Caco-2 and MDCK-MDR-1 cells also showed that ivacaftor and its metabolite M6 are not substrates of P-gp, while its metabolite M1 is a P-gp substrate. However, ivacaftor and M1 were shown to inhibit digoxin transport *in vitro*, indicating inhibition of P-gp *in vitro*.

Systemic exposure to ivacaftor tended to increase during repeat oral dosing at toxicological dose levels to mice, rats, rabbits, and dogs, possibly due to accumulation in plasma, and time to peak plasma concentrations (t_{max}) increased with increasing dose levels. In addition, systemic exposure to ivacaftor's major metabolites (data not shown) was higher for M1 than for M6 for all 3 species measured (mice, rats, and dogs); however, M1 and M6 exposures were less than ivacaftor in these species.

In vitro protein binding of ivacaftor and metabolites M1 and M6 was high (>98%) *in vitro* in mouse, rat, dog, and human plasma and to isolated human plasma protein components. *In vivo*, ivacaftor did not bind to melanin containing tissues. Placental transfer of C-labelled ivacaftor after a single oral dose to pregnant rats and rabbits occurred, but the exposures to ivacaftor in fetuses were low and variable. C-labelled ivacaftor accumulated in the milk of lactating rats.

Ivacaftor was excreted predominately in the feces of all species evaluated.

In vitro inhibition studies suggested that ivacaftor and M1 may have a drug-drug interaction potential through inhibition of CYP2C8, CYP2C9, CYP3A, and P-gp.

The pharmacokinetics of ivacaftor is similar between healthy adult volunteers and patients with CF. Table 11 shows the pharmacokinetic parameters of ivacaftor in healthy subjects following a single 150 mg oral dose in the fed and fasted conditions

Table 11 - Mean (SD) Pharmacokinetic Parameters of Ivacaftor Following a Single 150 mg Dose in Healthy Adult Subjects (N=18)						
	C_{max} (ng/mL)	T_{max}	t_½ (hr)	AUC_{0-∞} (ng*hr/mL)	Apparent Clearance (L/hr)	Apparent Volume of Distribution (L)
Fasted	218 (110)	16.7 (4.9)	3620 (1840)	50.6 (21.8)	1230 (707)	218 (110)
Fed	768 (233)	12 (2.7)	10600 (5260)	17.3 (8.4)	286 (149)	768 (233)

Absorption: After oral administration of a single 150 mg dose to healthy volunteers in the fasted state, peak plasma concentrations occurred at approximately 4 hours (t_{max}), and the mean (SD) for AUC_{0-∞} and C_{max} were 3620 (1840) ng*hr/mL and 218 (110) ng/mL, respectively. In the same study, oral administration of a single 150 mg dose in the fed state led to a substantial increase in exposure: AUC_{0-∞} was 10600 (5260) ng*hr/mL and C_{max} was 768 (233) ng/mL; t_{max} was unchanged.

After every 12-hour dosing, steady-state plasma concentrations of ivacaftor were reached by Days 3 to 5, with an accumulation ratio ranging from 2.2 to 2.9.

The exposure of ivacaftor increased approximately 2.5- to 4-fold when given with food containing fat. Therefore, KALYDECO should be administered with fat-containing food. The median (range) t_{max} is approximately 4.0 (3.0; 6.0) hours in the fed state.

The effect of food on ivacaftor absorption is similar for KALYDECO granules and the 150 mg tablet formulation.

Distribution: Ivacaftor is approximately 99% bound to plasma proteins, primarily to alpha 1-acid glycoprotein and albumin. Ivacaftor does not bind to human red blood cells.

The apparent volume of distribution of ivacaftor is similar in healthy subjects and patients with CF. After oral administration of 150 mg every 12 hours for 7 days to healthy volunteers in a fed state, the mean (SD) for apparent volume of distribution was 353 (122) L.

Metabolism: Ivacaftor is extensively metabolized in humans. *In vitro* and clinical studies indicate that ivacaftor is primarily metabolized by CYP3A. M1 and M6 are the two major

metabolites of ivacaftor in humans. M1 has approximately 1/6th the potency of ivacaftor and is considered pharmacologically active. M6 has less than 1/50th the potency of ivacaftor and is not considered pharmacologically active.

Elimination: Following oral administration, the majority of ivacaftor (88%) is eliminated in the feces after metabolic conversion. The major metabolites M1 and M6 accounted for approximately 65% of the total dose eliminated with 22% as M1 and 43% as M6. There was negligible urinary excretion of ivacaftor as unchanged parent. The apparent terminal half-life was approximately 12 hours following a single dose in the fed state. The apparent clearance (CL/F) of ivacaftor was similar for healthy subjects and patients with CF. The mean (SD) of CL/F for a single 150 mg dose was 17.3 (8.4) L/hr in healthy adult subjects.

Special Populations and Conditions

Pediatrics: Ivacaftor exposure in pediatric patients 12 months to <6 years of age administered KALYDECO granules, 50 mg every 12 hours (weight 7 kg to <14 kg) or 75 mg every 12 hours (weight 14 kg to <25 kg), was similar to that observed in adults administered KALYDECO tablets, 150 mg every 12 hours. Ivacaftor exposure observed in Phase 2 and 3 studies as determined using population pharmacokinetic (PK) analysis is presented by age group (and body weight for patients less than 12 years of age) in Table 12. Exposures in 6- to 11-year-olds are predictions based on simulations from the population PK model using data obtained for this age group.

Age Group	Dose	C _{min, ss} (ng/mL)	AUC _{ss} (ng*h/mL)
4 months to less than 6 months (≥5 kg)	25 mg q12h	371 (183)	6480 (2520)
6 months to less than 12 months (5 kg to <7 kg) *	25 mg q12h	336	5410
6 months to less than 12 months (7 kg to <14 kg)	50 mg q12h	508 (252)	9140 (4200)
12 months to less than 24 months (7 kg to <14 kg)	50 mg q12h	440 (212)	9050 (3050)
12 months to less than 24 months (≥14 kg to <25 kg)	75 mg q12h	451 (125)	9600 (1800)
2- to 5-year-olds (<14 kg)	50 mg q12h	577 (317)	10500 (4260)
2- to 5-year-olds (≥14 kg to <25 kg)	75 mg q12h	629 (296)	11300 (3820)
6- to 11-year-olds (≥14 kg to <25 kg)	75 mg q12h	641 (329)	10760 (4470)
6- to 11-year-olds (≥25 kg)	150 mg q12h	958 (546)	15300 (7340)
12- to 17-year-olds	150 mg q12h	564 (242)	9240 (3420)
Adults (≥18 years old)	150 mg q12h	701 (317)	10700 (4100)
* Values based on data from a single patient; standard deviation not reported			

Geriatrics: The efficacy and safety of KALYDECO in patients age 65 years or older have not been established.

Sex: Population pharmacokinetic analysis of data from clinical trials of KALYDECO indicated

that there was no clinically relevant effect of gender on the clearance of ivacaftor

Pregnancy and Breast-feeding:

No adequate and well-controlled studies of KALDYECO in pregnant women have been conducted. Because animal reproduction studies are not always predictive of human response, KALDYECO should be used during pregnancy only if the potential benefits outweigh the potential risks [see 7.1 Special Populations].

Ivacaftor is excreted into the milk of lactating female rats. Excretion of ivacaftor into human milk is probable. There are no human trials that have investigated the effects of ivacaftor on breastfed infants. The use of KALYDECO by nursing women should only be considered if the expected benefit to the patient outweighs the potential risk to the breastfed infant.

Hepatic Insufficiency: Adult subjects with moderately impaired hepatic function (Child-Pugh Class B, score 7 to 9) had similar ivacaftor C_{max} but an approximately 2-fold increase in ivacaftor $AUC_{0-\infty}$ compared with healthy subjects matched for demographics. Based on these results, a reduced KALYDECO dose of one tablet or packet of granules once daily is recommended for patients 6 months of age and older with moderate hepatic impairment. The impact of mild hepatic impairment (Child-Pugh Class A, score 5 to 6) on the pharmacokinetics of ivacaftor has not been studied, but the increase in ivacaftor $AUC_{0-\infty}$ is expected to be less than 2-fold. Therefore, no dose adjustment is necessary for patients 6 months of age and older with mild hepatic impairment. The impact of severe hepatic impairment (Child-Pugh Class C, score 10 to 15) on the pharmacokinetics of ivacaftor has not been studied. The magnitude of increase in exposure in these patients is unknown but is expected to be substantially higher than that observed in patients with moderate hepatic impairment. When benefits are expected to outweigh the risks, KALYDECO should be used with caution in patients with severe hepatic impairment at a starting dose of one tablet or packet of granules every other day and modified according to tolerability and clinical response [see Table 2 in 4.2 Recommended Dose and Dosage Adjustment]. The use of KALYDECO in patients 4 months to less than 6 months of age with hepatic impairment is not recommended.

Renal Insufficiency: Pharmacokinetic studies have not been performed with KALYDECO in patients with renal impairment. No dose adjustments are recommended for patients with mild or moderate renal impairment because of minimal urinary excretion of ivacaftor as unchanged parent (<0.01%) and minimal elimination of ivacaftor and its metabolites in urine (only 6.6% of total radioactivity was recovered in the urine in a human PK study); however, caution is recommended when administering KALYDECO to patients with severe renal impairment (creatinine clearance less than or equal to 30 mL/min) or end stage renal disease.

11 STORAGE, STABILITY AND DISPOSAL

Store at 20-25°C; excursions permitted to 15-30°C.

Keep out of the sight and reach of children.

12 SPECIAL HANDLING INSTRUCTIONS

The release of pharmaceuticals in the environment should be minimized. Medicines should not be disposed of via wastewater and disposal through household waste should be avoided.


Use established “collection systems” if available.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance

Proper name/ Common name:	ivacaftor (INN)
Chemical name:	<i>N</i> -(2,4-di- <i>tert</i> -butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide or <i>N</i> -(2,4-di- <i>tert</i> -butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide
Empirical formula:	C ₂₄ H ₂₈ N ₂ O ₃
Molecular Weight	392.49
Structural formula:	



Physicochemical properties:	KALYDECO is a white to off white powder that is practically insoluble in water (<0.05 microgram/mL)
-----------------------------	---

14 CLINICAL TRIALS

14.1 Trial Design and Study Demographics

The efficacy of KALYDECO in patients with CF was demonstrated in five Phase 3, randomized double-blind, placebo-controlled trials (Trial 1, 2, 3, 4, and 5).

Patients with CF with a *G551D* Mutation in the *CFTR* Gene

Table 13: Summary of Patient Demographics for Clinical Trials in CF Patients with a <i>G551D</i> <i>CFTR</i> mutation					
Study #	Trial design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
Trial 1 (subjects with a <i>G551D</i> - <i>CFTR</i> mutation)	Randomized, placebo-controlled, double-blind, parallel-group, multiple-dose, multi-centered	150 mg of KALYDECO or placebo; oral; every 12 hours with food for 48 weeks	161	26 years (12 to 53 years)	Male: 48% Female: 52%
Trial 2 (subjects with a <i>G551D</i> - <i>CFTR</i> mutation)	Randomized, placebo-controlled, double-blind, parallel-group, multiple-dose, multi-centered	150 mg of KALYDECO or placebo; oral; every 12 hours with food for 48 weeks	52	9 years (6 to 12 years)	Male: 48% Female: 52%

Dose Ranging

Dose ranging for the clinical program consisted primarily of one double-blind, placebo-controlled, crossover trial in 39 adult (mean age 31 years) Caucasian patients with CF who had FEV1 \geq 40% predicted. Twenty patients with median predicted FEV1 at baseline of 56% (range: 42% to 109%) received KALYDECO 25, 75, 150 mg or placebo every 12 hours for 14 days and 19 patients with median predicted FEV1 at baseline of 69% (range: 40% to 122%) received KALYDECO 150 mg, 250 mg, or placebo every 12 hours for 28 days. The selection of the 150 mg every 12 hours dose was primarily based on nominal improvements in lung function (pre dose FEV1) and changes in pharmacodynamic parameters (sweat chloride and nasal potential difference). The twice daily dosing regimen was primarily based on an apparent terminal plasma half life of approximately 12 hours. Selection of the 150 mg dose of KALYDECO for children 6 to 11 years of age was based on achievement of comparable pharmacokinetics for the key pharmacokinetic parameter as those observed for adult patients.

Efficacy

The efficacy of KALYDECO in patients with CF who have a *G551D* mutation in the *CFTR* gene was evaluated in two randomized, double-blind, placebo-controlled Phase 3 clinical trials (Trial 1 and Trial 2) in 213 clinically stable patients with CF (109 receiving KALYDECO 150 mg twice daily). All eligible patients from these trials were rolled over into an open-label extension study.

Patients who had persistent *Burkholderia cenocepacia*, *Burkholderia dolosa*, or *Mycobacterium abscessus* isolated from sputum at screening and those with abnormal liver function defined as 3 or more liver function tests (ALT, AST, AP, GGT, total bilirubin) \geq 3 x ULN were excluded.

Patients in both trials were randomized in a 1:1 ratio to receive either 150 mg of KALYDECO or placebo every 12 hours with food containing fat for 48 weeks in addition to their prescribed CF

therapies (e.g., tobramycin, dornase alfa). The use of inhaled hypertonic saline was not permitted.


Trial 1 evaluated 161 patients with CF and a G551D–CFTR mutation who were 12 years of age or older (mean age 26 years) with FEV₁ at screening between 40–90% predicted (mean FEV₁ 64% predicted at baseline [range: 32% to 98%]).

Trial 2 evaluated 52 patients with CF and a G551D–CFTR mutation who were 6 to 11 years of age (mean age 9 years) with FEV₁ at screening between 40–105% predicted (mean FEV₁ 84% predicted at baseline [range: 44% to 134%]).

The primary efficacy endpoint in both trials was improvement in lung function as determined by the mean absolute change from baseline in percent predicted pre-dose FEV₁ through 24 weeks of treatment.

In both trials, treatment with KALYDECO resulted in a significant improvement in FEV₁. The treatment difference between KALYDECO and placebo for the mean absolute change in percent predicted FEV₁ from baseline through Week 24 was 10.6 percentage points ($P < 0.0001$) in Trial 1 and 12.5 percentage points ($P < 0.0001$) in Trial 2 (Figure 1). These changes persisted through 48 weeks. Improvements in percent predicted FEV₁ were observed regardless of age, disease severity, sex, and geographic region.

Figure 1. Mean absolute change from baseline in percent predicted FEV₁*



* Primary endpoint was assessed at the 24-week time point.

Other Clinical Endpoints

Other efficacy variables included absolute change in sweat chloride from baseline to Week 24, absolute change in weight from baseline to Week 48, and absolute change in pooled (adult and child versions) Cystic Fibrosis Questionnaire Revised (CFQ-R) respiratory domain score from baseline to Week 24 (the CFQ-R is a disease specific, patient reported, health related, quality of life measure for cystic fibrosis consisting of generic and CF specific scales). The respiratory domain was used as an assessment tool for clinically relevant respiratory symptoms such as cough, wheezing, congestion, sputum production, and difficulty breathing. Time to first pulmonary exacerbation through Week 48 was also assessed in Trial 1. For the purpose of the trial, a pulmonary exacerbation was defined as a change in antibiotic therapy (IV, inhaled, or oral) as a result of 4 or more of 12 pre-specified sinopulmonary signs/symptoms. Patients

treated with KALYDECO demonstrated statistically significant improvements in risk of pulmonary exacerbations, CF symptoms (in Trial 1 only), and gain in body weight (Table 14). Weight data, when expressed as body mass index normalized for age and sex in patients <20 years of age, was consistent with absolute change from baseline in weight.

Table 14: Effect of KALYDECO on Other Efficacy Endpoints in Trials 1 and 2				
Endpoint	Trial 1		Trial 2	
	Treatment difference^a (95% CI)	P value	Treatment difference^a (95% CI)	P value
Mean absolute change from baseline in CF symptom score (points)^b				
Through Week 24	8.1 (4.7, 11.4)	<0.0001	6.1 (-1.4, 13.5)	0.1092
Through Week 48	8.6 (5.3, 11.9)	<0.0001	5.1 (-1.6, 11.8)	0.1354
Mean absolute change from baseline in sweat chloride (mmol/L)				
Through Week 24	-47.9 (-51.3, -44.5)	<0.0001	-54.3 (-61.8, -46.8)	<0.0001
Through Week 48	-48.1 (-51.5, -44.7)	<0.0001	-53.5 (-60.9, -46.0)	<0.0001
Relative risk of pulmonary exacerbation				
Through Week 24	0.40 ^c	0.0016	NA	NA
Through Week 48	0.46 ^c	0.0012	NA	NA
Mean absolute change from baseline in body weight (kg)				
At Week 24	2.8 (1.8, 3.7)	<0.0001	1.9 (0.9, 2.9)	0.0004
At Week 48	2.7 (1.3, 4.1)	0.0001	2.8 (1.3, 4.2)	0.0002
CI: confidence interval; NA: not analyzed due to low incidence of events				
^a Treatment difference = effect of KALYDECO – effect of Placebo				
^b Evaluated using the Cystic Fibrosis Questionnaire-Revised (CFQ-R)				
^c Hazard ratio for time to first pulmonary exacerbation				

Patients with CF with a G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R or G970R Mutation in the CFTR Gene

Table 15: Summary of Patient Demographics for Clinical Trials in Patients with CF with a G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R or G970R Mutation in the CFTR Gene					
Study #	Trial design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
Trial 4 (subjects with at least one of the following non-G551D gating mutations: G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, or G970R)	Randomized, placebo-controlled, double-blind, crossover, multiple-dose, multi-centered	150 mg of KALYDECO or placebo; oral; every 12 hours with food for 8 weeks	39	23 years (6 to 57 years)	Male: 56% Female: 44%
The G970R mutation causes a splicing defect resulting in little-to-no CFTR protein at the cell surface; the resulting low level of protein can be potentiated by ivacaftor.					

Trial 4 was a Phase 3, two part, randomized, double blind, placebo-controlled, crossover trial (Part 1) with an open-label extension period (Part 2) to evaluate the efficacy and safety of ivacaftor in patients with CF who have a non-G551D gating mutation in the *CFTR* gene (G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, or G970R). Patients who completed Part 1 continued into the 16-week open-label Part 2 of the trial.

Trial 4 evaluated 39 patients with CF and a G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, or G970R CFTR mutation who were 6 years of age or older (mean age 23 years) with FEV₁ ≥40% predicted at screening (mean FEV₁ 78% predicted at baseline [range: 43% to 119%]).

In Part 1, patients were randomized 1:1 to receive either 150 mg of ivacaftor or placebo every 12 hours with food containing fat for 8 weeks in addition to their prescribed CF therapies during the first Treatment Period and crossed over to the other treatment for the second 8 weeks. Treatment Periods were separated by a 4- to 8-week Washout Period. The use of inhaled hypertonic saline was not permitted.

The primary efficacy endpoint was improvement in lung function as determined by the mean absolute change from baseline in percent predicted FEV₁ through 8 weeks of treatment. The treatment difference between ivacaftor and placebo was 10.7 percentage points (P<0.0001). Improvements in percent predicted FEV₁ were observed regardless of age, disease severity, sex, geographic region, and *Pseudomonas aeruginosa* infection status at baseline. In this study, statistically significant improvement in FEV₁ was seen at Day 15 and durable through 8 weeks.

Treatment with ivacaftor resulted in consistent and statistically significant treatment effects

across the secondary endpoints of absolute change from baseline in BMI and BMI for age-z score (0.7 kg/m²; $P < 0.0001$ and 0.3 points; $P = 0.0010$, respectively), and CFQ-R respiratory domain score (9.6 points; $P = 0.0004$) when compared to placebo. Together, these results demonstrate the positive effects of ivacaftor treatment on pulmonary and extrapulmonary measures.

Based on clinical (percent predicted FEV₁) and pharmacodynamic (sweat chloride) [see 10.2 Pharmacodynamics] responses to ivacaftor, efficacy in patients with the *G970R* mutation could not be established. The *G970R* mutation has been identified as causing a splicing defect resulting in little-to-no CFTR protein at the cell surface able to be potentiated by ivacaftor.

Patients with CF with an *R117H* Mutation in the CFTR Gene

Table 16: Summary of Patient Demographics for Clinical Trials in CF Patients with an <i>R117H</i> mutation in the CFTR Gene					
Study #	Trial design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
Trial 5 (subjects with an <i>R117H</i> -CFTR mutation)	Randomized, placebo-controlled, double-blind, parallel-group	150 mg of KALYDECO or placebo; oral; every 12 hours with food for 24 weeks	69	31 years (6 to 68 years)	Male: 44% Female: 56%

Trial 5 was a Phase 3, randomized, double blind, placebo-controlled, parallel group clinical trial to evaluate the efficacy and safety of ivacaftor in 69 patients 6 years of age and older with an *R117H* mutation in the CFTR gene. Patients who were 12 years and older had FEV₁ at screening between 40-90% predicted and patients who were 6-11 years of age had FEV₁ at screening between 40-105% predicted. The overall mean FEV₁ was 73% predicted at baseline (range: 33% to 106%). In the indicated patient population, 18 years of age and older, the mean FEV₁ was 65% predicted at baseline (range: 33% to 93%). All eligible patients from this trial were rolled over into an open-label extension study.

The patients had well preserved body mass index (BMIs) (mean overall: 23.8 kg/m²) and a high proportion were pancreatic sufficient as assessed by a low rate of pancreatic enzyme replacement therapy use (pancreatin: 11.6%; pancrelipase: 5.8%). Patients who had persistent Burkholderia cenocepacia, Burkholderia dolosa, or Mycobacterium abscessus isolated from sputum at screening and those with abnormal liver function defined as 3 or more liver function tests (ALT, AST, AP, GGT, total bilirubin) $\geq 3 \times$ ULN were excluded.

Patients were randomized 1:1 to receive either 150 mg of KALYDECO (n=34) or placebo (n=35) every 12 hours with food containing fat for 24 weeks in addition to their prescribed CF therapies.

The primary efficacy endpoint was improvement in lung function as determined by the mean absolute change from baseline in percent predicted FEV₁ through 24 weeks of treatment. The treatment difference for absolute change in percent predicted FEV₁ through Week 24 was 2.1 percentage points, which did not reach statistical significance ($P = 0.1979$).

Subgroup analysis according to age group was pre specified in this study protocol.

Subgroup Analysis of Patients less than 18 Years of Age

Efficacy with respect to mean FEV₁ has not been adequately established at this time.

Subgroup Analysis of Patients 18 Years of Age and Older

Treatment with ivacaftor (n=24) resulted in a significant improvement in absolute change in percent predicted FEV₁ through Week 24 compared to placebo (n=26), with a treatment difference of 5.0 percentage points (P=0.0119).

Other efficacy variables that were analyzed included absolute change in sweat chloride from baseline through Week 24, absolute change in BMI at Week 24, and improvement in cystic fibrosis symptoms through Week 24 as assessed by the CFQ-R respiratory domain score. The treatment difference for the absolute change from baseline in BMI was 0.31 kg/m² (95% CI - 1.9, 2.5). The treatment difference in CFQ-R respiratory domain score through Week 24 was 12.6 points (95% CI 5.0, 20.3).

Pediatric Patients with CF aged 4 Months to Less Than 6 Years with G551D or Another Gating Mutation

Study #	Trial design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
Trial 6 (subjects eligible for the trial had CF with a G551D, G1244E, G1349D, G178R, G551S, G970R, S1251N, S1255P, S549N, or S549R mutation in the CFTR gene)	Non-randomized, open-label, multiple-dose	50 mg KALYDECO granules or 75 mg KALYDECO granules according to weight; oral; every 12 hours for 24 weeks	34	2 to <6 years of age (mean age 3 years)	Male: 82% Female: 18%
Trial 7 (subjects with CF with at least one of the following gating mutations: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R)	Non-randomized, open-label	50 mg KALYDECO granules or 75 mg KALYDECO granules according to weight; oral; every 12 hours for 24 weeks	19	12 months to <24 months (mean age 15.2 months)	Male: 58% Female: 42%

	Non-randomized, open-label	50 mg KALYDECO granules according to weight; oral; every 12 hours for 24 weeks	11	6 months to <12 months (mean age 9.0 months)	Male: 18 % Female: 82 %
	Non-randomized, open-label, multidose	25 mg and 50 mg KALYDECO granules according to weight; oral; every 12 hours for 24 weeks	6	4 months to <6 months (mean age 4.5 months)	Male: 83% Female: 17%

The efficacy of KALYDECO in children 4 months to less than 24 months of age and 2 years to less than 6 years of age is extrapolated from efficacy in patients 6 years of age and older with support from population pharmacokinetic analyses showing similar drug exposure levels in adults and children 4 months to less than 6 years of age.

Trial 7 was a 2 part (Part A and Part B) non-randomized, open-label trial that evaluated patients with CF and a gating mutation aged less than 24 months. Patients were enrolled in cohorts based on age. The trial enrolled a cohort of 19 pediatric patients aged 12 months to less than 24 months (mean age 15.2 months at baseline) with 18 patients completing the 24-week treatment period. A cohort of 11 patients were aged 6 months to less than 12 months (mean age 9.0 months at baseline) with all 11 patients completing the 24-week treatment period. A cohort of 6 patients were aged 4 months to less than 6 months (mean age 4.5 months at baseline) with all 6 patients completing the 24-week treatment period.

Patients received ivacaftor 25 mg, 50 mg or 75 mg granules according to their age and weight at each study visit (patients weighing 5 to less than 7 kg received ivacaftor 25 mg, 7 kg to less than 14 kg received ivacaftor 50 mg, and patients weighing more than 14 kg received ivacaftor 75 mg). Ivacaftor was administered orally every 12 hours with fat-containing food in addition to standard-of-care CF therapies. All 19 patients aged 12 months to less than 24 months weighed <14 kg at baseline and were administered the 50 mg ivacaftor dose.

In Part B of Trial 7, the primary endpoint of safety was evaluated through 24 weeks [see 8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data]. Secondary endpoints were evaluation of pharmacokinetics and the absolute change from baseline in sweat chloride through 24 weeks of treatment [see 10.2 Pharmacodynamics]. Tertiary endpoints included growth parameters and measures of pancreatic function. Mean growth parameters were normal at baseline and generally maintained through 24 weeks of treatment. Improvements in fecal elastase-1 (a measure of exocrine pancreatic function) were observed by Week 2 and sustained through 24 weeks of treatment.

Patients with CF Homozygous for the *F508del* Mutation in the *CFTR* gene

Table 18: Summary of Patient Demographics for Clinical Trials in CF Patients Homozygous for the <i>F508del</i> Mutation in the <i>CFTR</i> gene					
Study #	Trial design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
Trial 3 (subjects homozygous for the <i>F508del-CFTR</i> mutation)	Randomized, placebo-controlled, double-blind, parallel-group, multiple-dose, multi-centered	150 mg of KALYDECO or placebo; oral; every 12 hours with food for 16 weeks	140	23 years (12 to 52 years)	Male: 53% Female: 47%

Trial 3 was a 16 week, randomized, double blind, placebo-controlled, parallel group trial in 140 patients with CF age 12 years and older who were homozygous for the *F508del* mutation in the *CFTR* gene and who had FEV₁ ≥40% predicted. The primary endpoint was improvement in lung function as determined by the mean absolute change from baseline through Week 16 in percent predicted FEV₁. Treatment with KALYDECO resulted in no improvement in FEV₁ relative to placebo. There were also no meaningful differences between patients treated with KALYDECO compared to placebo for secondary endpoints (change in CF symptoms, change in weight, or change in sweat chloride concentration).

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

The toxicity of ivacaftor was evaluated in acute, repeat-dose, genetic, carcinogenicity, developmental and reproductive, local tolerance, and other toxicity studies.

General Toxicology

Acute Toxicity

Ivacaftor demonstrated a low potential for acute toxicity from high single doses in both mice, (maximum tolerated dose [MTD] = 2000 mg/kg) and rats (MTD = 500 mg/kg). No ivacaftor-related adverse effects were seen at levels that represent 13 to 27 times the maximum recommended human dose (MRHD) on a mg/kg basis (assuming a 50 kg human).

Repeat-dose Toxicity

Ivacaftor was tested in repeat-dose studies of up to 3 months' duration in mice, 6 months' duration in rats, and 12 months' duration in dogs. The only target organ of toxicity identified for ivacaftor was the liver of mice and rats. Clinical chemistry and/or morphological evidence of hepatotoxicity was observed at high dosages in mice (≥600 mg/kg/day in a 3-month study) and rats (≥200 mg/kg/day in the 3-month study and ≥100 mg/kg/day in the 6-month study). In mice,

the main clinical pathology changes at the end of 3 months of dosing were elevated alanine aminotransferase (ALT), alkaline phosphatase (ALP), and serum electrolytes relative to the control group, and lower cholesterol and glucose, which was accompanied by minimal foci of hepatocellular necrosis in only a few of the animals. The main ivacaftor-related clinical pathology changes in rats (relative to the control group) included prolongation of prothrombin time (PT) and activated partial thromboplastin time (APTT); increases in ALT, gamma-glutamyltransferase (GGT), total protein, and blood urea nitrogen (BUN); serum electrolyte changes; and lower bicarbonate. Dose-related elevations in liver weights were accompanied by histopathological findings of centrilobular hepatocellular necrosis with acute/subacute inflammation in a few rats and mixed inflammatory cells occasionally seen in the liver. The hepatic enzyme elevations were typically less than 3-fold greater than normal. Occasional instances of atrioventricular (AV) block occurred in dogs in repeat-dose studies. AV block is a well-documented background finding in this species. In addition, a slight increase in the incidence of supraventricular premature complex (SVPC) runs was observed in the chronic (12-month) study. The SVPC runs, which occurred in only 3 out of 40 dogs in this study, consisted of multiple events within a single electrocardiogram (ECG) recording at dosages ≥ 30 mg/kg/day and were reversible following a 28-day recovery period. All other ECG parameters were normal in all groups and the SVPC runs were not accompanied by morphological changes in the heart or changes in the health status of these dogs. In the chronic toxicity studies, summed exposures to ivacaftor and its major metabolites at the no observed adverse effect level (NOAEL) in rats (50 mg/kg/day) and dogs (60 mg/kg/day) were at least 4.4- to 5.2- and 2.5- to 3.4-fold higher than the estimated steady-state summed AUC_{0-24hr} (117.8 $\mu\text{g hr/mL}$) at the recommended human therapeutic dosage, respectively (exposures were obtained by non-compartmental analysis (NCA) from sparse PK samples collected in Trial 4).

Carcinogenicity

Two-year studies in mice and rats to assess the carcinogenic potential of ivacaftor demonstrated that ivacaftor was not carcinogenic in either species. Plasma exposures to ivacaftor in mice at the non-carcinogenic dosage (200 mg/kg/day, the highest dosage tested) were approximately 4- to 7-fold higher than the plasma levels measured in humans following ivacaftor therapy and at least 1.2- to 2.4-fold higher with respect to the summed AUCs for ivacaftor and its major metabolites. Plasma exposures to ivacaftor in rats at the non-carcinogenic dosage (50 mg/kg/day, the highest dosage tested) were approximately 16- to 29-fold higher than the plasma levels measured in humans following ivacaftor therapy, and 6- to 9-fold higher with respect to the summed AUCs for ivacaftor and its major metabolites (exposures were obtained by non-compartmental analysis (NCA) from sparse PK samples collected in Trial 4).

Genotoxicity

Ivacaftor was shown to be non-mutagenic and non-clastogenic in the following standard *in vitro* and *in vivo* genotoxicity tests: Ames test for bacterial gene mutation, *in vitro* chromosomal aberration assay in Chinese hamster ovary cells, and *in vivo* mouse micronucleus test.

Reproductive and Developmental Toxicity

Ivacaftor impaired fertility and reproductive performance indices in male and female rats at 200 mg/kg/day (yielding exposures approximately 8 and 5 times, respectively, the maximum recommended human dose (MRHD) based on the summed AUC of ivacaftor and its major

metabolites; exposures were obtained by non-compartmental analysis (NCA) from sparse PK samples collected in Trial 4). Decreased weight of seminal vesicles in males and increases in prolonged diestrus in females were observed at 200 mg/kg/day. Ivacaftor decreased the fertility index in female rats and the number of corpora lutea, implantations, and viable embryos at 200 mg/kg/day when dams were dosed prior to and during early pregnancy. No effects on male or female fertility and reproductive performance indices were observed at ≤ 100 mg/kg/day (yielding exposures approximately 6 and 3 times respectively, the MRHD based on the summed AUCs of ivacaftor and its major metabolites). Ivacaftor was not teratogenic when dosed orally up to 200 mg/kg/day to pregnant rats and up to 100 mg/kg/day to pregnant rabbits during the organogenesis stage of fetal development, and did not cause developmental defects (learning and memory, reproductive capacity) in the offspring of pregnant rats dosed orally from pregnancy through parturition and weaning. M1 and M6 were not directly quantitated in the developmental and reproductive toxicity studies.

Juvenile Toxicity

Cataracts were seen in juvenile rats dosed with ivacaftor from postnatal Day 7 to 35 at dose levels of 10 mg/kg/day and higher (approximately 0.17 and 0.27 times the MRHD based on summed AUCs of ivacaftor and its metabolites in males and females, respectively); exposures were obtained by non-compartmental analysis (NCA) from sparse PK samples collected in Trial 4). This finding was not observed in older animals. The significance of these findings for humans is unknown.

Special Toxicology

Ivacaftor was not irritating to skin after topical administration to rabbits. Ivacaftor was classified as a non-irritant to eyes when tested *in vitro* on isolated bovine corneas (bovine corneal opacity and permeability assay). In a murine local lymph node assay, ivacaftor had no effects on the proliferative response of lymph node cells from the draining auricular lymph nodes, demonstrating that ivacaftor does not show the potential to induce skin sensitization.

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

**PrKALYDECO®
ivacaftor tablets
ivacaftor granules**

Read this carefully before you/your child start taking **KALYDECO** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your/your child's medical condition and treatment and ask if there is any new information about **KALYDECO**.

What is KALYDECO used for?

KALYDECO tablets (150 mg) are for the treatment of cystic fibrosis (CF):

- in patients aged 6 years and older and weighing 25 kg or more who have one of the following mutations in their cystic fibrosis transmembrane conductance regulator (*CFTR*) gene: *G551D*, *G1244E*, *G1349D*, *G178R*, *G551S*, *S1251N*, *S1255P*, *S549N* or *S549R*.
- in patients aged 18 years and older who have an *R117H* mutation in their *CFTR* gene.

KALYDECO granules (25 mg, 50 mg and 75 mg) are for the treatment of children with cystic fibrosis (CF):

- in patients aged 4 months and older and weighing 5 kg to less than 25 kg who have one of the following mutations in their *CFTR* gene: *G551D*, *G1244E*, *G1349D*, *G178R*, *G551S*, *S1251N*, *S1255P*, *S549N* or *S549R*.

KALYDECO is not for use in people with CF with two copies of the *F508del* mutation.

It is not known if KALYDECO is safe and effective in children under 4 months of age or weighing less than 5 kg.

How does KALYDECO work?

KALYDECO belongs to a group of medicines called “*cystic fibrosis transmembrane conductance regulator (CFTR) potentiators*.” The *CFTR* protein is a channel at the surface of the cell that allows the movement of particles such as chloride in and out of the cell, contributing to salt and water balance. KALYDECO helps this *CFTR* protein channel open more often allowing more chloride to pass through.

What are the ingredients in KALYDECO?

Medicinal ingredients: ivacaftor

Non-medicinal ingredients:

Tablets (150 mg): carnauba wax, colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, indigo carmine aluminum lake, lactose monohydrate, magnesium stearate, microcrystalline cellulose, PEG 3350, polyvinyl alcohol, sodium lauryl sulfate, talc, and titanium dioxide. The printing ink contains ammonium hydroxide, iron oxide black, propylene glycol, and shellac.

Granules (25 mg, 50 mg, 75 mg): colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, mannitol, sucralose, and sodium lauryl sulfate.

KALYDECO comes in the following dosage forms:

- Tablets: 150 mg
- Granules: 75 mg, 50 mg, and 25 mg

Do not use KALYDECO if:

- You are allergic (hypersensitive) to ivacaftor or to any of the non-medicinal ingredients or any of the ingredients in the component of the container.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take KALYDECO. Talk about any health conditions or problems you may have, including if you:

- have kidney or liver disease.
- have a problem with the lens of your eye (cataract). Your doctor may recommend eye exams before and after your treatment with KALYDECO.
- are pregnant or plan to become pregnant. It is not known if KALYDECO will harm your unborn baby. You and your doctor should decide if you will take KALYDECO while you are pregnant.
- are breastfeeding or planning to breastfeed. It is not known if KALYDECO passes into your breast milk. You and your doctor should decide if you will take KALYDECO while you are breastfeeding.

Other warnings you should know about:

Driving and using machines: You may get dizzy when you take KALYDECO. Wait to see how you feel after taking KALYDECO before you drive or use machines. **For children:** you or your child's caregiver should supervise your child when they take KALYDECO. Wait to see if your child is dizzy after taking KALYDECO before they ride their bikes or do anything else that needs their full attention.

Abnormal blood test results: KALYDECO can cause abnormal blood test results. Your doctor will decide if blood tests are needed.

If you have had high liver enzymes in the past, your doctor may order blood tests to check your liver more often.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with KALYDECO:

- antifungal medicines, such as ketoconazole, itraconazole, posaconazole, voriconazole, fluconazole
- antibiotics used for the treatment of bacterial infection, such as clarithromycin, erythromycin, rifampin, rifabutin
- phenobarbital, carbamazepine, phenytoin used for the treatment of epileptic seizures
- oral midazolam, alprazolam, diazepam, triazolam used for the treatment of anxiety, insomnia, agitation, etc.
- digoxin is used for the treatment of mild to moderate congestive heart failure and an abnormal heart rhythm called atrial fibrillation
- cyclosporine, tacrolimus are used after an organ transplantation
- warfarin is an anticoagulant used to prevent heart attacks, stroke, and blood clots
- St. John's wort (*Hypericum perforatum*) is an herbal medicine
- grapefruit juice and grapefruit

Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

How to take KALYDECO:

- Always take KALYDECO exactly how your doctor tells you.
- Take your doses of KALYDECO 12 hours apart.
- Even if you feel well, keep taking KALYDECO exactly how your doctor tells you.
- Check with your doctor if you are not sure about your dose.
- Do not change the dose or stop taking the medicine without first talking to your doctor.
- Your doctor may need to adjust your dose if you have liver disease or if you are taking medications that may interact with KALYDECO.

Usual dose:

KALYDECO Tablets (for patients aged 6 years and older and weighing 25 kg or more):

One tablet every 12 hours by mouth with fat containing food (see below). Do not crush or chew the tablet. Swallow the tablet whole.

- Each KALYDECO box contains 4 individual blister cards.
- There are 7 days of tablets for each blister card. Each blister card contains 14 tablets - 7 morning doses and 7 evening doses.
- You may cut along the dotted line to separate your doses from the blister card.
- **Morning Dose:** unpeel the paper backing from a blister card. Do not push the tablet through the paper backing because the tablets could break. Remove one KALYDECO tablet and swallow it whole with food that contains fat.
- **Evening Dose:** 12 hours after your first dose, unpeel the paper backing from another blister card to remove one KALYDECO tablet and swallow it whole with food that contains fat.

KALYDECO Granules (for children aged 4 months and older and weighing 5 kg to less than 25 kg): Your doctor will prescribe the appropriate amount based on age and weight. The usual dose is to take 1 packet of granules every 12 hours with fat-containing food.

How to prepare the granules:

- Each KALYDECO box contains 4 individual wallets.
- There are 7 days of granules in each wallet. Each wallet contains 14 packets of granules - 7 morning doses and 7 evening doses.
- Finish all doses from one wallet before starting a new one.
- **Morning Dose:** Remove the first dose from the wallet.
- Hold the packet with cut line on top.
- Shake the packet gently to settle the KALYDECO granules.
- Tear or cut packet open along cut line.
- Carefully pour all of the KALYDECO granules in the packet into 1 teaspoon of soft food or liquid. Food or liquid should be at or below room temperature. Each packet is for single use only. Some examples of soft foods or liquids include puréed fruits or vegetables, yogurt, applesauce, water, milk, or juice (except for grapefruit juice).
- Mix the KALYDECO granules with food or liquid.
- **After mixing, give KALYDECO within 1 hour. Make sure all medicine is taken. This is very important for KALYDECO to work properly and be effective.**
- If mixed with food, KALYDECO granules must not be stored for future use.
- **Evening Dose:** This dose should be taken 12 hours after your **Morning Dose**. Follow the same steps listed above under **Morning Dose**.

KALYDECO should always be taken with a fat containing food:

- Taking KALYDECO with fat containing food is important to get the right amount of medicine in your body.
- Each dose should be taken just before or just after fat containing food.
- Meals and snacks recommended in CF guidelines or meals recommended in standard nutritional guidelines contain adequate amounts of fat. A serving size of foods appropriate

- for age from a typical CF diet should be given.
- Examples of meals that contain fat:
 - meals prepared with butter or oils
 - meals that have eggs, nuts, whole milk dairy products (such as whole milk, cheese, and yogurt) or meats.

Overdose:

If you think you, or a person you are caring for, have taken too much KALYDECO, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

- If you miss a dose of KALYDECO and it is **within 6 hours** of when you usually take it, take your missed dose of KALYDECO as prescribed with fat-containing food as soon as possible.
- If you miss a dose of KALYDECO and it is more **than 6 hours** after the time you usually take it, **skip** that dose only and take the next dose when you usually take it. Do not take 2 doses at the same time to make up for your missed dose.

What are possible side effects from using KALYDECO?

These are not all the possible side effects you may have when taking KALYDECO. If you experience any side effects not listed here, tell your healthcare professional.

- | | |
|--|--|
| <ul style="list-style-type: none"> • Diarrhea • Nausea • Stomach (abdominal) pain • Common cold • Runny nose • Upper respiratory tract infection • Changes in the type of bacteria in your sputum | <ul style="list-style-type: none"> • Headache • Dizziness • Nasal congestion • Sinus congestion • Sore throat • Rash • Joint pain |
|--|--|

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
UNCOMMON			
Liver disorder: Yellowing of the skin or eyes, dark urine, abdominal pain, nausea, vomiting, loss of appetite, pale stools, itchy skin		√	
Abdominal pain (stomach)	√		
Low blood sugar (glucose): Sweating, shakiness, weakness, hunger, nausea, dizziness, headache	√		

UNKNOWN			
Allergic reaction: rash; swelling of the face, lips, tongue or throat; difficulty swallowing or breathing			√

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store at 20-25°C; short periods to 15-30°C are permitted.
Keep out of reach and sight of children.

If you want more information about KALYDECO:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer’s website <http://www.vrtx.ca>, or by calling 1-877-634- 8789.

This leaflet was prepared by Vertex Pharmaceuticals (Canada) Incorporated.

© 2021 Vertex Pharmaceuticals (Canada) Incorporated

Vertex and KALYDECO are registered trademarks of Vertex Pharmaceuticals Incorporated.

Last Revised Aug 24, 2021